GlobeNewswire·May 11, 2026, 4:30 PM ET

STERIS Announces Financial Results for Fiscal 2026 Fourth Quarter and Full Year

Full year fiscal 2026 revenue from continuing operations increased 9% to $5.9 billion, with constant currency organic growth at 7%.
As reported diluted EPS from continuing operations for fiscal 2026 rose to $7.93, while adjusted diluted EPS increased to $10.17.
The Board approved a new $1 billion share repurchase program to replace the prior authorization.
Fourth quarter fiscal 2026 revenue from continuing operations grew 7% to $1.6 billion, with constant currency organic growth of 5%.
Healthcare segment revenue grew 7% to $1.14 billion in the fourth quarter, driven by service, consumable, & capital equipment increases.
Applied Sterilization Technologies (AST) revenue increased 6% to $289.2 million in the fourth quarter, with service revenue up 10% but capital equipment down 62%.
Life Sciences revenue rose 9% to $162.9 million in the fourth quarter, fueled by 19% growth in capital equipment.
Fiscal 2026 net cash provided by operations was $1.34 billion, & free cash flow reached $982.9 million.
Fiscal 2027 revenue is expected to increase 7-8% as reported, with constant currency organic growth anticipated at 6-7%.
Adjusted diluted EPS for fiscal 2027 is projected to range from $11.10 to $11.30, representing a 9-11% increase.
Capital expenditures for fiscal 2027 are estimated at $375 million, including a $60 million investment for a new sterility assurance plant in Mentor, Ohio.
A conference call to discuss results is scheduled for May 12, 2026, at 9:00 a.m. ET.